A Dark Vector Cognition product

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

74K characters. Original on sec.gov ·

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The 38 tables in Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

MD&AOverview

Management's Discussion and Analysis of Financial Condition and Results of Operations

The discussion and analysis presented below is concerned with material changes in financial condition and results of operations, including amounts and certainty of cash flows from operations and from outside sources, between the periods specified in our condensed consolidated balance sheets at March 31, 2026 and June 30, 2025, and in our condensed consolidated statements of earnings and our condensed consolidated statements of cash flows for the three and nine months ended March 31, 2026 and 2025. All comparisons presented are with respect to the prior-year period, unless stated otherwise. The discussion and analysis in this Form 10-Q should be read in conjunction with the MD&A included in our 2025 Form 10-K.

2Cardinal Health | Q3 Fiscal 2026 Form 10-Q
MD&AOverview

Overview of Consolidated Results

Revenue

Revenue for the three months ended March 31, 2026 increased 11 percent to $60.9 billion from the comparative prior-year quarter, primarily due to branded and specialty pharmaceutical sales growth from existing customers. Revenue for the nine months ended March 31, 2026 increased 17 percent to $190.6 billion from the comparative prior-year period, primarily due to branded and specialty pharmaceutical sales growth from existing and new customers.

GAAP and Non-GAAP Operating Earnings

Three Months Ended March 31,Nine Months Ended March 31,
(in millions)20262025Change20262025Change
GAAP operating earnings$509$730(30)%$1,884$1,8472%
State opioid assessment related to prior fiscal years——(17)—
Restructuring and employee severance25286661
Amortization and other acquisition-related costs114152348331
Acquisition-related cash and share-based compensation costs1122024320
Impairments and (gain)/loss on disposal of assets, net185(17)173(15)
Litigation (recoveries)/charges, net11(105)(7)(176)
Non-GAAP operating earnings$956$80718%$2,690$2,06730%

The sum of the components and certain computations may reflect rounding adjustments.

GAAP operating earnings for the three and nine months ended March 31, 2026 decreased 30 percent to $509 million and increased 2 percent to $1.9 billion from the comparative prior-year periods, respectively. GAAP operating earnings for the three and nine months ended March 31, 2026 was unfavorably impacted by the $184 million pre-tax non-cash goodwill impairment charge related to the Navista & ION reporting unit within the Pharma segment recognized in the current quarter, the $106 million and $165 million of net recoveries in class action antitrust litigation recognized in the comparative prior-year periods, respectively, and higher cash and share-based compensation costs resulting from the timing of acquisitions within The Specialty Alliance. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 4 of the "Notes to the Condensed Consolidated Financial Statements" for further information on the goodwill impairment.

Non-GAAP operating earnings for the three and nine months ended March 31, 2026 increased 18 percent to $956 million and 30 percent to $2.7 billion from the comparative prior-year periods, respectively. GAAP and non-GAAP operating earnings for the three and nine months ended March 31, 2026 were favorably impacted by increased contribution from branded and specialty pharmaceutical products, the impact of the acquisitions of management services organization ("MSO") platforms and Advanced Diabetes Supply Group ("ADS"), and the performance of our generics program.

3Cardinal Health | Q3 Fiscal 2026 Form 10-Q
MD&AOverview

GAAP and Non-GAAP Diluted EPS

Three Months Ended March 31,Nine Months Ended March 31,
($ per share)2026 (2)2025 (2)Change2026 (2)2025 (2)Change
GAAP diluted EPS (1)$1.69$2.10(20)%$5.54$5.442%
State opioid assessment related to prior fiscal years——(0.05)—
Restructuring and employee severance0.080.090.210.19
Amortization and other acquisition-related costs0.300.481.081.02
Acquisition-related cash and share-based compensation costs0.460.060.980.06
Impairments and (gain)/loss on disposal of assets, net0.59(0.06)0.56(0.04)
Litigation (recoveries)/charges, net0.06(0.32)0.04(0.51)
Non-GAAP diluted EPS (1)$3.17$2.3535%$8.35$6.1636%

The sum of the components and certain computations may reflect rounding adjustments.

(1)Diluted earnings per share attributable to Cardinal Health, Inc. ("diluted EPS").

(2)The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures."

GAAP diluted EPS for the three months ended March 31, 2026 decreased 20 percent to $1.69 from the comparative prior-year quarter, primarily due to the factors impacting GAAP operating earnings discussed in the preceding section, partially offset by favorable changes in discrete tax items. GAAP diluted EPS for the nine months ended March 31, 2026 increased 2 percent to $5.54 from the comparative prior-year period, primarily due to the factors impacting GAAP operating earnings discussed in the preceding section and favorable changes in discrete tax items, partially offset by increased interest expense.

Non-GAAP diluted EPS for the three and nine months ended March 31, 2026 increased 35 percent to $3.17 and 36 percent to $8.35 from the comparative prior-year periods, respectively, primarily due to the factors impacting non-GAAP operating earnings discussed in the preceding section and favorable changes in discrete tax items, partially offset by increased interest expense.

4Cardinal Health | Q3 Fiscal 2026 Form 10-Q
MD&AOverview

Significant Developments in Fiscal 2026 and Trends

Pharmaceutical and Specialty Solutions Segment

Solaris Health Acquisition

On November 3, 2025, we, through The Specialty Alliance, completed the acquisition of Solaris Health, a urology MSO, for a purchase price of approximately $1.9 billion in cash, subject to certain adjustments. In connection with the closing of this transaction, we issued common units in The Specialty Alliance to certain physicians and members of management which are estimated to have a grant date fair value of approximately $500 million, a portion of which will be recognized as post-combination expense within acquisition-related cash and share-based compensation costs.

Solaris Health includes more than 750 providers across more than 250 practice locations in 14 states. Solaris Health is part of The Specialty Alliance, our multi-specialty MSO platform, and their results are reported within our Pharma segment. With the closing of this transaction, we own approximately 76% of The Specialty Alliance. We funded the acquisition with a combination of cash proceeds from the recent debt financing and cash on hand. See Note 5 of the "Notes to Condensed Consolidated Financial Statements" for additional information on the debt financing.

Management Service Organization Platforms

The performance of our MSO platforms positively impacted the year-over-year comparison of Pharma segment profit during the three and nine months ended March 31, 2026, primarily due to the impact of the acquisitions of GI Alliance ("GIA"), Urology America, and Solaris Health. The Specialty Alliance is our multi-specialty MSO platform, which is primarily comprised of GIA, Urology America, Solaris Health and other gastroenterology- and urology-focused practices. Navista is our oncology MSO platform, which is primarily comprised of ION and other oncology-focused practices. Our ability to successfully provide physician practice support and management services, and to receive the value we expect to receive from our recent acquisitions of MSO platforms, depends upon a number of factors, including: the ability to develop or acquire and integrate appropriate practice management and support expertise; the ability to support recruitment, integration, and retention of sufficient numbers of local providers and staff; ensuring the alignment of interests between Cardinal Health and the physicians; the ability to successfully support negotiations with vendors, suppliers, and payors; the reimbursement and regulatory environment; and competition from other healthcare organizations.

Branded Pharmaceuticals

During the three and nine months ended March 31, 2026, we saw an increased demand for GLP-1 pharmaceuticals which positively impacted our Pharma segment and consolidated revenue for the three and nine months ended March 31, 2026; however, increased GLP-1 sales did not meaningfully contribute to segment profit. Future demand for these medications is unpredictable and our ability to meet demand may be impacted by supply constraints. Additionally, the recently issued Executive Order titled “Delivering Most-Favored Nation Prescription Drug Pricing to American Patients” and other administrative policies or actions may impact sales or profitability of branded pharmaceutical products; however, the extent of the impact is uncertain and may vary depending on the timeline for implementation and the extent of any price reductions.

Generics Program

The performance of our Pharma segment generics program positively impacted the year-over-year comparison of Pharma segment profit during the three and nine months ended March 31, 2026. The Pharma segment generics program includes, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes, the Red Oak Sourcing, LLC venture ("Red Oak Sourcing") with CVS Health Corporation ("CVS Health"), and generic pharmaceutical contract manufacturing and sourcing costs.

The frequency, timing, magnitude, and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, generic pharmaceutical manufacturer pricing changes, and generic pharmaceutical contract manufacturing and sourcing costs all impact Pharma segment profit and are subject to risks and uncertainties. These risks and uncertainties may impact Pharma segment profit and consolidated operating earnings during the remainder of fiscal 2026 and beyond.

5Cardinal Health | Q3 Fiscal 2026 Form 10-Q
MD&AOverview

Tariffs

In February 2025, the United States imposed tariffs under the International Emergency Economic Powers Act ("IEEPA") on certain goods, materials and products imported into the United States from countries where we do business. In February 2026, the U.S. Supreme Court ruled that the IEEPA tariffs were unlawful but did not establish a mechanism for issuing refunds. Subsequent to this ruling, U.S. Customs and Border Protection ("CBP") worked to establish a phased process to administer refunds required by the Supreme Court ruling; however, uncertainty remains concerning the timing, scope and administrative process to receive refunds for all IEEPA tariffs paid. In April 2026, CBP launched its program to administer Phase 1 refund requests; however, substantially all of our IEEPA tariffs paid will fall under Phase 2 or later phases. As of the date hereof, CBP has not communicated a date on which the refund process for such Phase 2 or later phases will be established or available.

We have taken actions to reduce the impact of IEEPA and other tariffs on our financial results, including through cost optimization initiatives and by increasing prices on impacted products to customers; however, these measures have not fully offset the negative impact. As of the third quarter of fiscal year 2026, we have paid approximately $200 million in IEEPA tariffs, primarily related to products that we source, manufacture or distribute in our GMPD segment. In the event that we receive refunds of IEEPA tariffs from the government, we expect to return to those customers the portion of those refunds that reflect the estimated increased prices paid related to IEEPA tariffs.

We have not recognized any financial impact related to potential tariff refunds or payments to our customers as of March 31, 2026. The ultimate resolution of this matter could positively impact our results of operations in future periods, including GMPD segment profit and consolidated operating income.

Following the Supreme Court IEEPA ruling, the U.S. government replaced IEEPA tariffs with tariffs imposed under Section 122 of the Trade Act of 1974. We continue to evaluate the impact of these and other tariffs, including tariffs imposed under Sections 301 and 232 of the Trade Act of 1974.

Tariff rates remain dynamic and we do not expect to be able to establish alternative sources of supply or otherwise mitigate the potential impact of tariffs on all of the products that we source, manufacture or distribute. We are still incurring increased costs from tariffs, and if we are not successful at increasing prices to customers, our financial results will continue to be negatively impacted. Additionally, if tariffs are modified in the future, or our information is incorrect regarding their impact, we may not be able to respond to such changes adequately or in a timely manner and our financial results could be negatively impacted. Furthermore, if our competitors do not increase prices, or increase prices to a lesser extent than we do or are able to offset the impact of tariffs through other actions, our competitive and financial position may be adversely affected.

6Cardinal Health | Q3 Fiscal 2026 Form 10-Q
MD&AResults of Operations

Results of Operations

Revenue

141516

Three Months Ended March 31,Nine Months Ended March 31,
(in millions)20262025Change20262025Change
Pharmaceutical and Specialty Solutions$56,111$50,43311%$175,985$149,27218%
Global Medical Products and Distribution3,1483,160—%9,5919,4372%
Other1,7061,30431%5,0713,77334%
Total segment revenue60,96554,89711%190,647162,48217%
Corporate(25)(19)N.M.(71)(63)N.M.
Total revenue$60,940$54,87811%$190,576$162,41917%

Pharmaceutical and Specialty Solutions

Pharma segment revenue for the three months ended March 31, 2026 increased 11 percent to $56.1 billion from the comparative prior-year quarter, primarily due to branded and specialty pharmaceutical sales growth from existing customers.

Pharma segment revenue for the nine months ended March 31, 2026 increased 18 percent to $176.0 billion from the comparative prior-year period, primarily due to branded and specialty pharmaceutical sales growth from existing and new customers.

Global Medical Products and Distribution

GMPD segment revenue for the three months ended March 31, 2026 was flat at $3.1 billion compared to the prior-year quarter. This reflected lower distribution volumes, offset by Cardinal Health brand growth.

GMPD segment revenue for the nine months ended March 31, 2026 increased 2 percent to $9.6 billion from the comparative prior-year period, primarily due to Cardinal Health brand growth, partially offset by lower distribution volumes.

Other

Other segment revenue for the three and nine months ended March 31, 2026 increased 31 percent to $1.7 billion and 34 percent to $5.1 billion from the comparative prior-year periods, respectively, due to growth across at-Home Solutions (including the acquisition of ADS), Nuclear and Precision Health Solutions, and OptiFreight® Logistics.

7Cardinal Health | Q3 Fiscal 2026 Form 10-Q
MD&AResults of Operations

Cost of Products Sold

Cost of products sold for the three and nine months ended March 31, 2026 increased 11 percent to $58.4 billion and 17 percent to $183.4 billion from the comparative prior-year periods, respectively, primarily due to the factors affecting the changes in revenue and gross margin.

Gross Margin

1920

Three Months Ended March 31,Nine Months Ended March 31,
(in millions)20262025Change20262025Change
Gross margin$2,498$2,12318%$7,214$5,96621%

Gross margin for the three and nine months ended March 31, 2026 increased 18 percent to $2.5 billion and 21 percent to $7.2 billion from the comparative prior-year periods, respectively, primarily due to the acquisitions of MSO platforms and ADS, increased contribution from branded and specialty pharmaceutical products, and the performance of our generics program.

Gross margin rates for the three and nine months ended March 31, 2026 grew 23 basis points to 4.10 percent and 12 basis points to 3.79 percent from the comparative prior-year periods, respectively, primarily due to the acquisition of MSO platforms, partially offset by the impact of the unfavorable changes in product mix in the Pharma segment. These changes in product mix were primarily driven by increased pharmaceutical distribution branded sales, which have a dilutive impact on our overall gross margin rate.

Distribution, Selling, General and Administrative ("SG&A") Expenses

Three Months Ended March 31,Nine Months Ended March 31,
(in millions)20262025Change20262025Change
SG&A expenses$1,542$1,31517%$4,507$3,89816%

SG&A expenses for the three and nine months ended March 31, 2026 increased 17 percent to $1.5 billion and 16 percent to $4.5 billion from the comparative prior-year periods, respectively, primarily due to the acquisitions of MSO platforms and ADS.

8Cardinal Health | Q3 Fiscal 2026 Form 10-Q
MD&AResults of Operations

Segment Profit

We evaluate segment performance based on segment profit, among other measures. See Note 12 of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.

Three Months Ended March 31,Nine Months Ended March 31,
(in millions)20262025Change20262025Change
Pharmaceutical and Specialty Solutions$784$66218%$2,138$1,72324%
Global Medical Products and Distribution2539(36)%1086566%
Other17913434%52435647%
Total segment profit98883518%2,7702,14429%
Corporate(479)(105)N.M.(886)(297)N.M.
Total consolidated operating earnings$509$730(30)%$1,884$1,8472%

Pharmaceutical and Specialty Solutions

Pharma segment profit for the three months ended March 31, 2026 increased 18 percent to $784 million from the comparative prior-year quarter, primarily due to increased contribution from branded and specialty pharmaceutical products and the performance of our generics program.

Pharma segment profit for the nine months ended March 31, 2026 increased 24 percent to $2.1 billion from the comparative prior-year period, primarily due to increased contribution from branded and specialty pharmaceutical products, the acquisition of MSO platforms, and the performance of our generics program.

Global Medical Products and Distribution

GMPD segment profit for the three months ended March 31, 2026 decreased 36 percent to $25 million from the comparative prior-year quarter, primarily due to the adverse net impact of tariffs.

GMPD segment profit for the nine months ended March 31, 2026 increased 66 percent to $108 million from the comparative prior-year period, primarily due to growth from existing customers, partially offset by the adverse net impact of tariffs.

Other

Other segment profit for the three and nine months ended March 31, 2026 increased 34 percent to $179 million and 47 percent to $524 million from the comparative prior-year periods, respectively, primarily due to the performance of at-Home Solutions (including the acquisition of ADS), OptiFreight® Logistics, and Nuclear and Precision Health Solutions.

Corporate

The changes in Corporate for the three and nine months ended March 31, 2026 were due to the factors discussed in the "Other Components of Consolidated Operating Earnings" section that follows.

9Cardinal Health | Q3 Fiscal 2026 Form 10-Q
MD&AResults of Operations

Other Components of Consolidated Operating Earnings

In addition to revenue, gross margin, and SG&A expenses discussed previously, consolidated operating earnings were impacted by the following:

Three Months Ended March 31,Nine Months Ended March 31,
(in millions)2026202520262025
Restructuring and employee severance$25$28$66$61
Amortization and other acquisition-related costs114152348331
Acquisition-related cash and share-based compensation costs1122024320
Impairments and (gain)/loss on disposal of assets, net185(17)173(15)
Litigation (recoveries)/charges, net11(105)(7)(176)

Restructuring and Employee Severance

During the three and nine months ended March 31, 2026 and 2025, restructuring and employee severance costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and certain initiatives to rationalize our manufacturing operations.

Amortization and Other Acquisition-Related Costs

Amortization of acquisition-related intangible assets was $95 million and $266 million for the three and nine months ended March 31, 2026, respectively, and $77 million and $214 million for the three and nine months ended March 31, 2025, respectively.

Transaction and integration costs associated with acquisitions were $19 million and $82 million for the three and nine months ended March 31, 2026, respectively, and $75 million and $117 million for the three and nine months ended March 31, 2025, respectively.

Acquisition-related Cash and Share-based Compensation Costs

Acquisition-related cash and share-based compensation costs were $112 million and $243 million for the three and nine months ended March 31, 2026 and $20 million for both the three and nine months ended March 31, 2025. The increase primarily resulted from the timing of acquisitions within The Specialty Alliance.

Impairments and (Gain)/Loss on Disposal of Assets, Net

We recognized a pre-tax goodwill impairment charge of $184 million related to the Navista & ION reporting unit within the Pharma segment during the three and nine months ended March 31, 2026, as discussed further in the "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 4 of the "Notes to the Condensed Consolidated Financial Statements".

Litigation (Recoveries)/Charges, Net

We recognized income for net recoveries in class action antitrust litigation in which we were a class member or plaintiff of $106 million and $165 million during the three and nine months ended March 31, 2025, respectively.

Earnings Before Income Taxes

In addition to the items discussed above, earnings before income taxes were impacted by the following:

Three Months Ended March 31,Nine Months Ended March 31,
(in millions)20262025Change20262025Change
Other (income)/expense, net$16$(9)N.M.$(5)$(11)N.M.
Interest expense, net1017436%26914191%

Interest Expense, Net

Interest expense, net for the three and nine months ended March 31, 2026 increased 36 percent to $101 million and 91 percent to $269 million from the comparative prior-year periods, respectively, primarily due to the additional debt financing for our recent acquisitions.

10Cardinal Health | Q3 Fiscal 2026 Form 10-Q
MD&AResults of Operations

Provision for Income Taxes

The effective tax rate was 3.1 percent and 19.4 percent for the three and nine months ended March 31, 2026, respectively, and 23.6 percent and 22.8 percent for the three and nine months ended March 31, 2025, respectively. The effective tax rate for the three and nine months ended March 31, 2026 was primarily impacted by discrete planning benefits.

Tax Effects of Goodwill Impairment Charges

During the three months ended March 31, 2026, we recognized a pre-tax goodwill impairment charge of $184 million related to the Navista & ION reporting unit within the Pharma segment. The net tax benefit related to this charge is $23 million for fiscal 2026.

The tax effect of the goodwill impairment charge recorded during the three months ended March 31, 2026 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we have recorded other goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill did not materially impact the annual effective tax rate for 2026.

11Cardinal Health | Q3 Fiscal 2026 Form 10-Q
MD&ALiquidity and Capital Resources

Liquidity and Capital Resources

We currently believe that, based on available capital resources and projected operating cash flow, we have adequate capital resources to fund our operations and expected future cash needs as described below. In addition to those disclosed, if we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.

Cash and Equivalents

Our cash and equivalents balance was $3.9 billion at both March 31, 2026 and June 30, 2025.

During the nine months ended March 31, 2026, net cash provided by operating activities was $3.5 billion, which includes the impact of normal timing of payments to vendors and payments totaling $417 million related to the opioid litigation.

During the nine months ended March 31, 2026, we deployed $1.9 billion for the Solaris Health acquisition, $600 million for debt repayment, $1.0 billion for share repurchases, $371 million for dividends, and $385 million for capital expenditures. We issued new long-term debt and received net proceeds of approximately $1.0 billion to fund a portion of the consideration paid in connection with the Solaris Health acquisition and for general purposes.

At March 31, 2026, our cash and equivalents were held in cash depository accounts with major banks or invested in high quality, short-term liquid investments.

Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of customer payments, inventory purchases, payments to vendors, and tax payments in the regular course of business, as well as fluctuating working capital needs driven by customer and product mix.

The cash and equivalents balance at March 31, 2026 includes $612 million of cash held by subsidiaries outside of the United States.

Other Financing Arrangements and Financial Instruments

Credit Facilities and Commercial Paper

In addition to cash and equivalents and operating cash flow, other sources of liquidity at March 31, 2026 include a $3.0 billion commercial paper program, backed by a $2.0 billion revolving credit facility that expires in February 2028 and a $1.0 billion 364-Day revolving credit facility that expires in October 2026. We also have a $1.0 billion committed receivables sales facility through September 2028. During the three months ended March 31, 2026, under our commercial paper program and our committed receivables program, we had maximum combined total daily amounts outstanding of $2.0 billion and an average combined daily amount outstanding of $179 million. At March 31, 2026, we had no amounts outstanding under our commercial paper program, revolving credit facilities, or our committed receivables sales facility.

In September 2025, we renewed our committed receivables sales facility program through Cardinal Health 23 Funding, LLC ("CHF") through September 2028.

In October 2025, we renewed the 364-Day revolving credit facility, under which we have access to $1.0 billion of committed liquidity through October 2026.

Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of March 31, 2026, we were in compliance with this financial covenant.

Long-Term Debt and Other Short-Term Borrowings

We had total long-term obligations, including the current portion and other short-term borrowings, of $8.9 billion and $8.5 billion at March 31, 2026 and June 30, 2025, respectively.

In August 2025, we issued additional debt, with the aggregate principal amount of $1.0 billion, to fund a portion of the consideration payable in connection with the Solaris Health acquisition and for general purposes. The notes issued are $600 million aggregate principal amount of 4.5% Notes that mature on September 15, 2030 and $400 million aggregate principal amount of 5.15% Notes that mature on September 15, 2035. The proceeds of the notes issued, net of discounts, premiums, and debt issuance costs, were approximately $1.0 billion.

During the three months ended March 31, 2026, we made a partial principal payment of $100 million for the Floating Rate Term Loan due 2028 with available cash.

During the nine months ended March 31, 2026, we repaid the full principal of $500 million of the 3.75% Notes due 2025 at maturity with available cash.

12Cardinal Health | Q3 Fiscal 2026 Form 10-Q
MD&ALiquidity and Capital Resources

Capital Deployment

Opioid Litigation Settlements

We had $4.3 billion accrued at March 31, 2026 related to certain national opioid litigation settlements, as further described within Note 6 of the "Notes to Condensed Consolidated Financial Statements." We expect the majority of the remaining payment amounts to occur through 2038. During the nine months ended March 31, 2026, we made our fifth annual payment of $366 million under National Opioid Settlement Agreement (the "NOSA") and other settlement payments of $51 million related to the opioid litigation. The amounts of future annual payments under the NOSA may differ from the payments that we have already made.

Capital Expenditures

Capital expenditures during the nine months ended March 31, 2026 and 2025 were $385 million and $315 million, respectively.

Dividends

On each of May 5, 2025, August 15, 2025, November 4, 2025, and February 12, 2026, our Board of Directors approved a quarterly dividend of $0.5107 per share, or $2.04 per share on an annualized basis, which were paid on July 15, 2025, October 15, 2025, January 15, 2026, and April 15, 2026 to shareholders of record on July 1, 2025, October 1, 2025, January 2, 2026 and April 1, 2026, respectively.

Share Repurchases

During the nine months ended March 31, 2026, we deployed $1.0 billion for repurchases of our common shares under accelerated share repurchase ("ASR") programs. We funded the repurchases with available cash. See Note 10 of the "Notes to Condensed Consolidated Financial Statements" for additional information.

Solaris Health Acquisition

On November 3, 2025, we, through The Specialty Alliance, completed the acquisition of Solaris Health, a urology MSO, for a purchase price of approximately $1.9 billion in cash, subject to certain adjustments. In connection with the closing of this transaction, we issued common units in The Specialty Alliance to certain physicians and management which are estimated to have a grant date fair value of approximately $500 million, a portion of which will be recognized as post-combination expense. See Note 2 of the "Notes to Condensed Consolidated Financial Statements" for additional information.

13Cardinal Health | Q3 Fiscal 2026 Form 10-Q
MD&AOther Items

Other Items

The MD&A in the 2025 Form 10-K addresses our contractual obligations and cash requirements, as of and for the fiscal year ended June 30, 2025. Other than the considerations noted above in connection with the Solaris Health acquisition and our debt issuance, there have been no subsequent material changes outside of the ordinary course of business to those items. See Note 2 and Note 5 of the "Notes to Condensed Consolidated Financial Statements" for additional information.

Critical Accounting Policies and Sensitive Accounting Estimates

Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management’s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Estimates are inherently uncertain, therefore actual results may differ, including due to the risks discussed in "Risk Factors" and other risks discussed in our 2025 Form 10-K and our other filings with the SEC since June 30, 2025.

Goodwill

Purchased goodwill is tested for impairment annually or when indicators of impairment exist. Goodwill impairment testing involves a comparison of the estimated fair value of reporting units to the respective carrying amount, which may be performed utilizing either a qualitative or quantitative assessment. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined that it is more likely than not that the fair value does not exceed the carrying amount, then a quantitative test is performed. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. A reporting unit is defined as an operating segment or one level below an operating segment (also known as a component).

Our reporting units are: Pharmaceutical and Specialty Solutions (excluding Navista & ION, The Specialty Alliance), Navista & ION, The Specialty Alliance, GMPD, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics.

Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. Our qualitative evaluation considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount.

Navista & ION Goodwill

Due to certain reductions in our long-term financial plan assumptions during the three months ended March 31, 2026, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for Navista & ION. Our determination of the estimated fair value of the Navista & ION Unit is based on a combination of the income-based approach (using a

discount rate of 10.5 percent and a terminal growth rate of 3 percent), and a market-based approach. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method and 20 percent to the guideline public company method. The carrying amount exceeded the estimated fair value, which resulted in a pre-tax impairment charge of $184 million for Navista & ION, which was recognized during the three months ended March 31, 2026 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. The impairment charge was primarily due to changes in the risk profile of the business plans, resulting in an increase in the discount rate. These changes reflect business model updates and base operational performance. The carrying value of Navista & ION at March 31, 2026 after recognizing the impairment charge was $1.1 billion, of which $909 million was goodwill. See Note 4 of the "Notes to Condensed Consolidated Financial Statements" for further discussion.

While we consider the assumptions used in our determination of the estimated fair value of Navista & ION to be reasonable and appropriate, they are complex and subjective, and additional adverse changes in one key assumption or a combination of key assumptions during fiscal 2026 may significantly affect future estimates. These assumptions include, among other things, a failure to meet expected earnings or other financial plans, including the execution of new opportunities as a result of the business model change, a decrease in future cash flows, an increase in the discount rate or a decrease in the terminal growth rate; increases in tax rates; or a significant change in industry or economic trends.

Adverse changes in key assumptions may result in a decline in fair value below the carrying value in the future and therefore, an impairment for Navista & ION goodwill in future periods, which could adversely affect our results of operations. For example, if we were to increase the discount rate by a hypothetical 0.5 percent to 11.0 percent or decrease the terminal growth rate by a hypothetical 1.0 percent to 2.0 percent, the fair value for Navista & ION would have further decreased by approximately $70 million.

14Cardinal Health | Q3 Fiscal 2026 Form 10-Q
Explanation and Reconciliation of Non-GAAP Financial Measures

Explanation and Reconciliation of Non-GAAP Financial Measures

The "Overview of Consolidated Results" section within MD&A in this Form 10-Q contains financial measures that are not calculated in accordance with GAAP.

In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated.

Exclusions from Non-GAAP Financial Measures

Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors’ assessment of the business for the reasons identified below:

  • LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies’ financial results. We did not recognize any LIFO charges or credits during the periods presented.

  • State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals due to changes in estimates or when the underlying assessments were invalidated by a court or reimbursed by manufacturers.

  • Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business and include, but are not limited to, costs related to divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance, and realigning operations.

  • Amortization and other acquisition-related costs, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets and amortization as a result of basis differences in equity method investments are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current, and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity’s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity, and size of acquisitions.

  • Acquisition-related cash and share-based compensation costs are incurred in connection with contingent cash payments or the issuance of share-based payment awards, which include service requirements, as a part of certain physician practice acquisitions. These costs include fair value adjustments for liability-classified awards. These costs are excluded because they are unrelated to the underlying operating results of our business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies’ financial results. In addition, the magnitude of these expenses is significantly impacted by the timing and size of the acquisitions of physician practices.

15Cardinal Health | Q3 Fiscal 2026 Form 10-Q
Explanation and Reconciliation of Non-GAAP Financial Measures
  • Impairments and gain or loss on disposal of assets, net are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current, and forecasted financial results.

  • Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.

The tax effect for each of the items listed above is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.

Definitions

Growth rate calculation: growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results.

Non-GAAP operating earnings: operating earnings excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net.

Non-GAAP earnings before income taxes: earnings before income taxes excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net.

Non-GAAP net earnings attributable to non-controlling interests: net earnings attributable to non-controlling interests excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net, each net of tax.

Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net, each net of tax.

Non-GAAP effective tax rate: provision for income taxes adjusted for the tax impacts of (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net, divided by (earnings before income taxes adjusted for the items above).

Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding.

16Cardinal Health | Q3 Fiscal 2026 Form 10-Q
Explanation and Reconciliation of Non-GAAP Financial Measures

GAAP to Non-GAAP Reconciliation

(in millions, except per common share amounts)Operating EarningsOperating Earnings Growth RateEarnings Before Income TaxesProvision for Income TaxesNet (Earnings)/Loss Attributable to Non-controlling InterestsNet Earnings****1Net Earnings****1 Growth RateDiluted EPS****1Diluted EPS****1 Growth Rate
Three Months Ended March 31, 2026
GAAP$509(30)%$392$12$19$399(21)%$1.69(20)%
Restructuring and employee severance25256—190.08
Amortization and other acquisition-related costs11411443—710.30
Acquisition-related cash and share-based compensation costs1121124—1080.46
Impairments and (gain)/loss on disposal of assets, net 218518522(23)1400.59
Litigation (recoveries)/charges, net1111(2)—130.06
Non-GAAP$95618%$840$86$(4)$75032%$3.1735%
Three Months Ended March 31, 2025
GAAP$73098%$665$157$(2)$50694%$2.1096%
Restructuring and employee severance28287210.09
Amortization and other acquisition-related costs15215234(2)1160.48
Acquisition-related cash and share-based compensation costs20201(4)150.06
Impairments and (gain)/loss on disposal of assets, net(17)(17)(4)(13)(0.06)
Litigation (recoveries)/charges, net(105)(105)(27)(78)(0.32)
Non-GAAP$80721%$741$166$(7)$56811%$2.3513%
Nine Months Ended March 31, 2026
GAAP$1,8842%$1,620$315$11$1,316—%$5.542%
State opioid assessments related to prior fiscal years(17)(17)(4)—(13)(0.05)
Restructuring and employee severance666615—510.21
Amortization and other acquisition-related costs34834892—2561.08
Acquisition-related cash and share-based compensation costs2432439—2340.98
Impairments and (gain)/loss on disposal of assets, net 217317319(23)1310.56
Litigation (recoveries)/charges, net(7)(7)(16)—90.04
Non-GAAP$2,69030%$2,426$430$(12)$1,98433%$8.3536%
Nine Months Ended March 31, 2025
GAAP$1,847N.M.$1,717$391$(4)$1,322N.M.$5.44N.M.
Restructuring and employee severance616115460.19
Amortization and other acquisition-related costs33133181(2)2481.02
Acquisition-related cash and share-based compensation costs20201(4)150.06
Impairments and (gain)/loss on disposal of assets, net(15)(15)(4)(11)(0.04)
Litigation (recoveries)/charges, net(176)(176)(51)(125)(0.51)
Non-GAAP$2,06714%$1,937$431$(10)$1,4956%$6.168%

1 Attributable to Cardinal Health, Inc.

2 For both the three and nine months ended March 31, 2026, impairments and (gain)/loss on disposals of assets, net includes pre-tax goodwill impairment charges of $184 million related to the Navista & ION reporting unit within the Pharma segment. For fiscal 2026, the estimated net tax benefit related to the impairments is $23 million and is included in the annual effective tax rate. The portion of the goodwill impairment charge attributable to noncontrolling interests is $23 million.

The sum of the components and certain computations may reflect rounding adjustments.

We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.

17Cardinal Health | Q3 Fiscal 2026 Form 10-Q
Other

Previous: Cover and table of contents · Next: Item 3. Quantitative and Qualitative Disclosures about Market Risk